WoS SCIE & CAS Academic Rankings
Global Journal Rankings & Directory
Explore academic hierarchies, Clarivate Impact Factors, Web of Science Q1–Q4 quartiles, and CAS divisions.
Showing 26–50 of 127 international scientific journals (Pharmacy)
| Rank | Journal Name & ISSN | Impact Factor | H-Index | WoS Quartile | Scopus SJR | CAS Division | Self-Citation | Docs/yr | Publisher |
|---|---|---|---|---|---|---|---|---|---|
| #26 | AAPS Pharmscitech ISSN: 1530-9932 | 5.1 | 130 | Q1 | 0.721Q1 | CAS Tier 3 | 2.9% | 297 | Springer International Publishing |
| #27 | European Journal of Pharmaceutical Sciences ISSN: 0928-0987 / 1879-0720 | 5.1 | 176 | Q1 | 0.951Q1 | CAS Tier 2 | 2.3% | 375 | Elsevier |
| #28 | Expert Opinion on Therapeutic Targets ISSN: 1472-8222 / 1744-7631Top Tier | 5.1 | 120 | Q1 | 1.383Q1 | CAS Tier 3 | 2.2% | 70 | Taylor and Francis Ltd. |
| #29 | European Journal of Pharmaceutics and Biopharmaceutics ISSN: 0939-6411 / 1873-3441 | 5 | 201 | Q1 | 0.848Q1 | CAS Tier 3 | 2.3% | 235 | Elsevier |
| #30 | Biomolecules & Therapeutics ISSN: 1976-9148 / 2005-4483 | 4.9 | 66 | Q1 | 0.969Q2 | CAS Tier 3 | 6.7% | 93 | Korean Society of Applied Pharmacology |
| #31 | Clinical Pharmacology & Therapeutics ISSN: 0009-9236 / 1532-6535Top Tier | 4.9 | 226 | Q1 | 1.856Q1 | CAS Tier 2 | 7.9% | 260 | Wiley-Blackwell |
| #32 | Molecular Pharmaceutics ISSN: 1543-8384 / 1543-8392 | 4.9 | 172 | Q2 | 0.957Q1 | CAS Tier 2 | 6.7% | 384 | American Chemical Society |
| #33 | Advances in Therapy ISSN: 0741-238X / 1865-8652 | 4.7 | 99 | Q2 | 1.418Q1 | CAS Tier 2 | 2.9% | 356 | Springer Healthcare |
| #34 | Drug Metabolism Reviews ISSN: 0360-2532 / 1097-9883Top Tier | 4.7 | 117 | Q1 | 0.93Q1 | CAS Tier 3 | 2.9% | 24 | Informa Healthcare |
| #35 | Expert Opinion on Therapeutic Patents ISSN: 1354-3776 / 1744-7674Top Tier | 4.7 | 98 | Q2 | 1.098Q1 | CAS Tier 3 | 1.9% | 66 | Taylor and Francis Ltd. |
| #36 | Journal of Drug Targeting ISSN: 1061-186X / 1029-2330 | 4.7 | 116 | Q1 | 0.829Q1 | CAS Tier 3 | 0% | 80 | Informa Healthcare |
| #37 | Pharmacoeconomics ISSN: 1170-7690 / 1179-2027 | 4.7 | 127 | Q1 | 1.807Q1 | CAS Tier 2 | 9.1% | 108 | Springer International Publishing |
| #38 | Expert Review of Anti-Infective Therapy ISSN: 1478-7210 / 1744-8336Top Tier | 4.6 | 110 | Q1 | 1.024Q1 | CAS Tier 3 | 2.4% | 116 | Taylor and Francis Ltd. |
| #39 | Pharmacological Reports ISSN: 1734-1140 / 2299-5684 | 4.5 | 104 | Q2 | 1.016Q1 | CAS Tier 3 | 0% | 135 | Springer International Publishing |
| #40 | Expert Opinion on Investigational Drugs ISSN: 1354-3784 / 1744-7658Top Tier | 4.3 | 126 | Q2 | 1.199Q1 | CAS Tier 3 | 0% | 97 | Taylor and Francis Ltd. |
| #41 | Journal of Pharmacology and Experimental Therapeutics ISSN: 0022-3565 / 1521-0103 | 4.3 | 254 | Q2 | 0.921Q2 | CAS Tier 3 | 6.5% | 145 | American Society for Pharmacology and Experimental Therapeutics |
| #42 | Clinical Pharmacokinetics ISSN: 0312-5963 / 1179-1926 | 4 | 197 | Q2 | 1.211Q1 | CAS Tier 2 | 4.3% | 113 | Springer International Publishing |
| #43 | Naunyn-Schmiedebergs Archives of Pharmacology ISSN: 0028-1298 / 1432-1912 | 4 | 104 | Q2 | 0.877Q2 | CAS Tier 3 | 6.5% | 134 | Springer Berlin Heidelberg |
| #44 | Pharmacotherapy ISSN: 0277-0008 / 1875-9114 | 4 | 136 | Q2 | 1.189Q1 | CAS Tier 3 | 6.9% | 102 | Wiley-Blackwell |
| #45 | Expert Opinion on Emerging Drugs ISSN: 1472-8214 / 1744-7623Top Tier | 3.8 | 59 | Q2 | 0.908Q2 | CAS Tier 3 | 0% | 31 | Taylor and Francis Ltd. |
| #46 | Clinical Therapeutics ISSN: 0149-2918 / 1879-114X | 3.7 | 158 | Q2 | 1.041Q1 | CAS Tier 3 | 0% | 169 | Elsevier Inc. |
| #47 | Journal of Natural Products ISSN: 0163-3864 / 1520-6025Top Tier | 3.7 | 173 | Q2 | 0.585Q1 | CAS Tier 2 | 6.1% | 351 | American Chemical Society |
| #48 | Journal of Pharmacy and Pharmacology ISSN: 0022-3573 / 2042-7158 | 3.7 | 148 | Q2 | 0.765Q2 | CAS Tier 3 | 0% | 193 | Wiley-Blackwell |
| #49 | Vascular Pharmacology ISSN: 1537-1891 / 1879-3649 | 3.7 | 114 | Q2 | 0.99Q2 | CAS Tier 3 | 2.9% | 66 | Elsevier Inc. |
| #50 | Drug Metabolism and Disposition ISSN: 0090-9556 / 1521-009X | 3.6 | 202 | Q2 | 1.054Q1 | CAS Tier 3 | 15.9% | 99 | American Society for Pharmacology and Experimental Therapeutics |